SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (350)12/7/2006 2:07:02 PM
From: rkrw  Read Replies (1) | Respond to of 362
 
Probably the correct call. Though I think probuphine looks interesting.

Vanda I think is overvalued. Their sleep drug is shaky imo. Wait until they show data in chronic insomnia, I wouldn't bet on it looking so good then. Iloperidone, can they get it past the qtc issues? I wouldn't bet on that either.



To: kenhott who wrote (350)12/7/2006 4:03:14 PM
From: DewDiligence_on_SI  Respond to of 362
 
If the safety profile is very clean (apart from the QT stuff), Iloperidone ought to have a chance to garner some respectable market share for patients who can’t tolerate the side effects of the most efficacious drugs (Zyprexa, Seroquel, and Risperdal). However, I don’t think Iloperidone has the efficacy to compete effectively for first-line treatment, so it’s unlikely that it will be a bona fide blockbuster.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News